Key Highlights
- Organogenesis reported Q2 2026 Revenue of $42.8 million, down about 58% year over year, largely due to Medicare reimbursement changes.
- The net loss reached $99.3 million, or $(0.77) per diluted share, sharply wider than the prior-year loss of $12.2 million.
- The company submitted a rolling Biologics License Application for ReNu, with a PDUFA target date of April 24, 2027.
Few 2026 stories in advanced wound care are as sharply defined as Organogenesis Holdings Inc. (ORGO), where a regulatory reimbursement shift has collided with the company's core revenue engine. The shares slipped in a recent session, but that small move sits against a far larger backdrop: a steep second-quarter revenue decline, a heavy net loss and a pending regulatory decision that could reshape the outlook. For this Nasdaq-listed regenerative-medicine company, the fundamentals are doing the talking.
Company and Latest Development
Organogenesis is a regenerative-medicine company focused on advanced wound care and surgical and sports medicine, with a portfolio that has long included skin-substitute and tissue products such as Apligraf and Dermagraft. In the second quarter of 2026, the company reported revenue of $42.8 million, down roughly 58% from $100.8 million a year earlier, and a net loss of $99.3 million, or $(0.77) per diluted share, sharply wider than the $12.2 million loss in the prior-year period. Management attributed the revenue collapse largely to Medicare reimbursement changes and related market disruption, and disclosed it had cut its direct sales force from about 180 representatives to 148, shifting surgical sales toward independent agencies.
What Is Driving Attention Around ORGO?
Unlike many screener-driven names, ORGO has a clearly identifiable pressure point: the impact of Medicare reimbursement changes on its wound-care business. The recent daily slip is minor next to that structural challenge, and no separate single-session catalyst is required to explain it. The dominant narrative is the sharp Q2 revenue drop, the large net loss, a delayed Dermagraft relaunch, and the company's ongoing regulatory effort behind its ReNu product. Attention is centered on whether Organogenesis can stabilize revenue and advance its pipeline while absorbing a significant reimbursement-driven hit.
Key Numbers and Company Position
The verified second-quarter 2026 figures frame the situation. Revenue was $42.8 million, down about 58% year over year. The net loss reached $99.3 million, with diluted EPS of $(0.77), versus a $(0.10) loss per share a year earlier, a swing that reflects the revenue decline and associated charges. The company reduced its direct sales headcount from roughly 180 to 148. On the regulatory front, Organogenesis submitted a rolling Biologics License Application for ReNu, with an assigned PDUFA target date of April 24, 2027. The Dermagraft relaunch has been delayed. The stock has traded near $1.57, with a market Capitalization around $200 million.
What Could Come Next?
Several company-specific milestones lie ahead. The ReNu BLA and its April 24, 2027 PDUFA date stand out as a potential long-term catalyst if the review advances. Investors may also watch for clarity on the timing of the delayed Dermagraft relaunch, the pace at which the reimbursement environment stabilizes, the effectiveness of the restructured surgical sales model, and quarterly revenue trends that show whether the Q2 decline is a trough or an ongoing trajectory. Any updated guidance or cost actions would also be relevant.
Risks to Watch
The risks are substantial. The Medicare reimbursement changes strike at the heart of Organogenesis's revenue base, and there is no guarantee the market disruption resolves quickly. The large net loss and steep revenue decline raise questions about profitability and cash management. Regulatory Risk applies to the ReNu BLA, where approval and timing are uncertain, and the delayed Dermagraft relaunch adds execution risk. Sales-force restructuring could disrupt commercial momentum, and competition across wound care and surgical markets remains intense.
Conclusion
Organogenesis Holdings is navigating a difficult stretch defined by a reimbursement-driven revenue shock, a heavy quarterly loss and a commercial reset. The modest share slip is a footnote next to those fundamentals. The developments worth monitoring are concrete: the ReNu BLA progress toward its April 2027 PDUFA date, the delayed Dermagraft relaunch, stabilization of the reimbursement backdrop, and whether restructured sales operations can steady revenue. For ORGO, the path forward hinges on execution and regulatory progress as it works to recover from a sharp downturn.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...